Anticoagulation in hospitalized patients with COVID-19

Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit o...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumann Kreuziger, Lisa, Sholzberg, Michelle, Cushman, Mary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Blood Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361053/
https://www.ncbi.nlm.nih.gov/pubmed/35653590
http://dx.doi.org/10.1182/blood.2021014527
Descripción
Sumario:Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.

Ejemplares similares